-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSLivre Blanc
Launch Excellence VI
Launch Excellence in a disrupted world: challenges and opportunity
Sep 10, 2019
Introduction
It is now very clear that the global pharmaceutical industry is in a period of significant change, and with it the environment for innovative product launch. Molecular innovation is being supplemented, and in some instances could be replaced, by other forms of innovation, including highly individualised and procedure-like cell and gene therapies, prescription digital therapeutics, or innovation on existing, off-patent molecules.
| The rise of specialty as the key value growth driver of the developed markets, has already created a situation where most launches, and almost 100% of the most successful launches, are for globally small, sometimes tiny, patient populations. 2018 was the first year in which both the FDA and the EMA approved more Orphan medicines, for rare diseases, than mainstream products. Mass market common, chronic diseases of the elderly don’t drive pharmaceutical value growth anymore; increasingly, the pipeline, the launches, and the pharmaceutical industry’s value growth is a product of high value therapies for small patient populations. IQVIA is in the unique position of having the largest global database on past launch performance available, giving us an unmatched quantitative evidence base in research on Launch. |
In this white paper, we make extensive use of our core MIDAS database of global launch sales, as well as, when we search into the past of launch, the MIDAS based World Review. In all cases, note that the value figures provided are at list price, pre-rebates and discounts, and at ex-manufacturer level. For our white paper, we focus on innovative, protected new products, defining these as New Active Substances (NAS). New Active Substances are novel and innovative active ingredients, small molecule, biologic or other, which have been launched on the global pharmaceutical market for the first time. |
| In our Launch Excellence series, we have defined the launch period as the first two years of a launch’s commercial life in a country, from the point sales first appear in MIDAS. Some argue the launch period can only start once a certain level of market access is obtained, although since market access processes and outcomes are highly variable by country this makes objective agreement on when “proper” launch has started across countries complex. For Thought Leadership, we’ve chosen objectivity and simplicity. However, we accept that the two-year initial launch period is only the start of many launches, albeit, because of the six-month window of opportunity which we will discuss later, an extremely important one. For multi-indicational products, launch is no longer a one-off event. In addition, faster approvals on earlier clinical data and longer journeys to full market access, because of extended real world assessment, create an extended launch period. |
There’s also consideration of the full lifetime value of a pharmaceutical launch. Unusual patterns of uptake, as for Hepatitis C products, create spectacular early launch performance but also rapid declines in performance. These products may have the steepest uptakes ever, but they are not the most valuable launches ever. The core of the Launch Excellence series examines the launches, which have been the most commercially successful in the recent timeframe, relative to their contemporaneous launch peers to each major launch country. By using largely consistent data and analytics since 2007 we build a unique, quantified view of the way in which commercial success has changed over years. Examining launches on a country by country basis means that we can understand the most common reasons why launches do not reach their full potential. |
The Past: The Most Successful Launches Of All Time
What is the ultimate measure of a Launch’s Excellence? Steep initial uptake curves, consistency of performance across major markets, and optimisation on the available opportunity are all extremely important. In the long view, however, the final assessment may be the total revenues the launch accrues during its full lifetime on the market.
| IQVIA can undertake this final assessment using its very long running World Review, published since the 1970s. More recent launches have an incomplete life, so we chose only launches for which we had a minimum of ten year’s World Review recorded sales. Despite the rise of specialty as the key launch value driver, it is still Lipitor, with an estimated $160bn of gross lifetime sales, that sits in the leader position of best-selling product of all time. But of the top 20, eight are primary care, and twelve specialty- even with these necessarily older products, specialty is winning in the long term. The world’s current largest selling product, Humira, is second in absolute lifetime sales and a specialty product ($145bn). Although the very best top sellers were also Excellent by our Launch Excellence criteria, the top sellers of all time can be either tortoises or hares - Launch Excellence uncovers, in the two-year evaluation period, the hares. |
Slower burn “tortoises” are also among the biggest selling products ever, notably Crestor, with an estimated $75bn of gross lifetime sales. Very commercially successful “tortoises” fail on Excellence criteria most often on measures of promotional out-performance, suggesting exceptionally high levels of promotional investment in the first two years of launch. This investment may also be accompanied by significant investment elsewhere. Crestor was not, by our two-year uptake criteria of previously Launch Excellences, an excellent launch. Consistent, careful investment over a period of a decade, including the GALAXY series of clinical trials which was, at the time, the largest patient number set of trials around a single product, have, in the longer term, paid off. However, such a lengthy and sustained level of investment will delay profitability. |
Download to read more and get the bonus appendix
Learn from past, present and future pharmaceutical launches in Launch Excellence in a disrupted world: Challenges and Opportunity